---
title: "Abbott Updates FY26 Guidance To Reflect Acquisition Of Exact Sciences"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282997106.md"
description: "Abbott (ABT) has updated its FY26 guidance, projecting adjusted EPS of $5.38 to $5.58, factoring in a $0.20 dilution from the acquisition of Exact Sciences. The company anticipates comparable sales growth of 6.5% to 7.5% for the year and expects second-quarter adjusted diluted EPS between $1.25 and $1.31. CEO Robert B. Ford emphasized that the acquisition enhances Abbott's growth potential. Following the announcement, Abbott shares fell 4.3% to $97.18 in pre-market trading."
datetime: "2026-04-16T12:10:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282997106.md)
  - [en](https://longbridge.com/en/news/282997106.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282997106.md)
---

# Abbott Updates FY26 Guidance To Reflect Acquisition Of Exact Sciences

(RTTNews) - Abbott (ABT) said it now projects full-year 2026 adjusted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences. Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%. The company projects second-quarter adjusted diluted earnings per share of $1.25 to $1.31.

Robert B. Ford, chairman and chief executive officer, said: "The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year."

On March 23, 2026, Abbott completed its acquisition of Exact Sciences.

In pre-market trading on NYSE, Abbott shares are down 4.3 percent to $97.18.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [EXAS.US](https://longbridge.com/en/quote/EXAS.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Harvest Portfolios Group Inc. Grows Holdings in Abbott Laboratories $ABT](https://longbridge.com/en/news/287027124.md)
- [Rayburn West Financial Services LLC Buys Shares of 16,587 Abbott Laboratories $ABT](https://longbridge.com/en/news/286395934.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Natera says EXPAND trial of Fetal Focus single-gene NIPT tops 2,000 enrollees](https://longbridge.com/en/news/287052322.md)
- [Lifeward Delays Quarterly Report Amid Deal Accounting](https://longbridge.com/en/news/286586728.md)